About
SPAS System is focused on the development and commercialization of a stent positioning assistance system (SPAS) for safer and faster percutaneous coronary intervention (PCI) procedures. SPAS is a torque-like accessory that allows accurate, mm-precise stent positioning, minimizing and potentially eliminating geographical misses. It also enables stent manipulation and placement without impairment of the PCI workflow; more confident performance by less experienced ICs; and a shorter procedural time for complex PCIs. SPAS is a class 2a device that is preloaded onto a stent delivery system. It has been validated on-bench, in silico, as the angio system for Simbionix, and in multiple clinical settings by industry leaders in Europe, Israel, and Russia. A 55-patient first-in-human multicenter clinical study conducted in Israel returned no device-related adverse events. All five investigators stated that SPAS improved their ability to control stent deployment and achieve better accuracy in its positioning. The overall mean operator SPAS accuracy and satisfaction scores were also very high. SPAS is the brand name of Seven Sons.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is SPAS System's primary product?
- SPAS System's primary product is SPAS, a stent positioning assistance system designed to improve the safety and speed of percutaneous coronary intervention (PCI) procedures.
- When was SPAS System founded?
- SPAS System was founded in February 2019.
- Where is SPAS System headquartered?
- SPAS System is headquartered in Herzliya, Israel.
- What is the current employee count for SPAS System?
- SPAS System currently has 5 employees.
- What is the regulatory classification of the SPAS device?
- The SPAS device is classified as a Class 2a medical device.
- Has the SPAS device undergone clinical validation?
- Yes, the SPAS device has been validated on-bench, in silico as the angio system for Simbionix, and in multiple clinical settings in Europe, Israel, and Russia. A 55-patient first-in-human multicenter clinical study in Israel reported no device-related adverse events.
- What is SPAS System's current funding stage?
- SPAS System is currently in the Pre-Funding stage.
- Who is a founder of SPAS System?
- Inna Martin is a founder of SPAS System.
- What are the primary geographic markets for SPAS System?
- SPAS System's primary geographic markets are Eastern Europe and Europe.